Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.453,79
0,07%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Acrivon Therapeutics Inc (ACRV) Acrivon Therapeutics Inc (ACRV) Notizie

Acrivon Therapeutics Inc

ACRV
8,45
-0,02 (-0,24%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
24/4/202422:01GLOBEAcrivon Therapeutics Reports Initial Positive Clinical Data..
17/4/202402:01GLOBEAcrivon Therapeutics to Host Corporate R&D Event..
10/4/202414:00GLOBEAcrivon Therapeutics Presents Data at AACR Annual Meeting..
09/4/202413:00GLOBEAcrivon Therapeutics Announces $130 Million Private..
28/3/202413:00GLOBEAcrivon Therapeutics Reports Fourth Quarter and Full Year..
06/3/202422:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202422:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/3/202422:30GLOBEAcrivon Therapeutics to Present Data at AACR Annual Meeting..
04/3/202414:15EDGAR2Form 8-K - Current report
04/3/202414:00GLOBEAcrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA,..
27/2/202414:00GLOBEAcrivon Therapeutics to Participate in a Panel Discussion at..
16/2/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202423:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202421:40EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202414:27EDGAR2Form 8-K - Current report
08/2/202414:00GLOBEAcrivon Therapeutics Appoints Seasoned Industry Executive..
06/2/202414:00GLOBEAcrivon Therapeutics to Present at the Oppenheimer 34th..
19/1/202422:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/1/202422:00GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
08/1/202413:28EDGAR2Form 8-K - Current report
04/1/202414:00GLOBEAcrivon Therapeutics to Present at the 42nd Annual J.P...
18/12/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/12/202322:21EDGAR2Form 8-K - Current report
01/12/202322:35EDGAR2Form S-3 - Registration statement under Securities Act of..
28/11/202314:58DJNAcrivon Therapeutics Gets FDA's Breakthrough Designation for..
28/11/202314:00GLOBEAcrivon Therapeutics Announces FDA has Granted Breakthrough..
21/11/202314:00GLOBEAcrivon Therapeutics Announces Inducement Grant Under Nasdaq..
17/11/202301:43EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/11/202301:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202315:12EDGAR2Form 8-K - Current report
09/11/202314:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202314:01GLOBEAcrivon Therapeutics Reports Third Quarter 2023 Financial..
20/10/202301:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/10/202314:00GLOBEAcrivon Therapeutics Presents Data Demonstrating..
29/9/202301:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/9/202301:13EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/9/202322:05GLOBEAcrivon Therapeutics Announces Inducement Grants Under..
19/9/202322:32GLOBEAcrivon Therapeutics to Highlight its ACR-368 OncoSignature..
05/9/202323:23EDGAR2Form 8-K - Current report
05/9/202322:05GLOBEAcrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1..
30/8/202314:00GLOBEAcrivon Therapeutics to Participate in Two Investor..
23/8/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 8,53 Min: 8,20 Max: 8,7794
Chiusura: 8,47

La tua Cronologia

NASDAQ
ACRV
Acrivon Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network